% Expired Patents = 100.0

Forward Citations = 22

Loading Chart...

3 inventors (with patents filed for the assignee):

David M White (4 out of 10 patents)

Barry G W Arnason (4 out of 5 patents)

Mark A Jensen (4 out of 5 patents)

4 patents: Sort by Forward Citations

1. 9127063 - Nucleic acids related to fusion proteins (2015-09-08),

2. 8986698 - Method of using fusion proteins (2015-03-24),

3. 8163289 - Methods and compositions involving polymeric immunoglobulin fusion proteins (2012-04-24),

4. 7897729 - Polymeric immunoglobulin fusion proteins that target low affinity FcγReceptors (2011-03-01),

Company Overview

Iterative Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for neurodegenerative diseases. With a team of experienced scientists and researchers, Iterative Therapeutics is dedicated to advancing novel treatment options to improve the lives of patients. Their cutting-edge approach combines in-depth research with state-of-the-art technology to create impactful solutions that address unmet medical needs.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

4 Patents

#666 in Chicago, IL

#2,840 in Illinois

#60,641 in US

Chicago, IL, United States of America

Iterative Therapeutics, Inc.

Forward Citations = 22

3 inventors:

David M White (4 out of 10 patents)

Barry G W Arnason (4 out of 5 patents)

Mark A Jensen (4 out of 5 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Iterative Therapeutics, Inc.. Retrieved from https://idiyas.com/company/iterative-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]